Fibrinogen, Plasminogen Activator Inhibitor-1, and Carotid Intima-Media Wall Thickness in the NHLBI Family Heart Study

Summary

Several studies have linked higher plasma fibrinogen and plasminogen activator inhibitor (PAI-1) concentrations with increased risk of cardiovascular disease. We studied whether members of families with increased occurrence of coronary heart disease (CHD) have increased levels of fibrinogen and PAI-1 and whether subclinical carotid atherosclerosis is associated with these two hemostatic factors. Contrary to our hypothesis, fibrinogen and PAI-1 antigen levels were not different between high CHD risk families versus random families. Adjusted for age and family type, fibrinogen and PAI-1 were both associated positively with carotid intima-media thickness assessed by B-mode ultrasound. However, adjustment for lifestyle and medical covariates essentially eliminated these associations. These data suggest 1) elevated fibrinogen and PAI-1 do not explain clustering of CHD in families and 2) fibrinogen and PAI-1 may partly mediate the effects of other risk factors on carotid atherosclerosis, though the data are also consistent with them playing no causal role.

• References

• 1 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
• 2 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
• 3 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-6.
• 4 Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
• 5 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM Study in Healthy Men. Arterioscler Thromb 1994; 14: 54-9.
• 6 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
• 7 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
• 8 Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
• 9 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tarazzi L, Tremoli E, Pozzili E, Turri M. for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13: 1412-7.
• 10 Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-36.
• 11 Salonen R, Seppanen K, Rauramaa R, Salonen JT. Prevalence of carotid atherosclerosis and serum cholesterol levels in east Finland. Arteriosclerosis 1988; 8: 788-92.
• 12 Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ. for the Cardiovascular Health Study Investigators. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1995; 15: 1269-79.
• 13 Agewall S, Wikstrand J, Suurküla M, Tengborn L, Fagerberg B. Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic disease. Blood Coagul Fibrinolysis 1994; 5: 895-904.
• 14 Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. The association of fibrinolytic parameters with early atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1995; 91: 284-90.
• 15 Perkins KA. Family history of coronary heart disease: is it an independent risk factor?. Am J Epidemiol 1986; 124: 182-94.
• 16 Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
• 17 Green F, Hamsten A, Blombäck M, Humphries S. The role of ß-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-20.
• 18 Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou J-P, Scarabin P-Y, Bara L, Green F, Cambien F. ß fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM Study. Circulation 1996; 93: 440-9.
• 19 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM Study. Thromb Haemost 1995; 74: 837-41.
• 20 Higgins M, Province M, Heiss G, Eckfeldt J, Ellison RC, Folsom A, Rao DC, Sprafka JM, Williams R. for the NHLBI Family Heart Study Investigators. The NHLBI Family Heart Study: Objectives and design. Am J Epidemiol 1996; 143: 1219-28.
• 21 Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chron Dis 1986; 39: 809-21.
• 22 Bond MG, Barnes R, Riley WA, Wilmoth SK, Chambless LE, Howard G, Owens B. High resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study (ARIC). J Neuroimag 1991; 1: 68-73.
• 23 Riley WA, Barnes R, Bond MG, Evans GW, Chambless L, Heiss G. High resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities Study (ARIC). J Neuroimag 1991; 1: 168-72.
• 24 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
• 25 Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
• 26 Warnick GR, Benderson JM, Albers JJ. Quantitation of high-density-lipoprotein subclasses after separation by dextran sulfate and Mg² precipitation. Clin Chem 1982; 28: 1574.
• 27 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
• 28 Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Littleton, MA: John Wright; 1982
• 29 Efron B. Bootstrap methods: another look at the jacknife. Ann Statist 1979; 7: 1-26.
• 30 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
• 31 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-9.
• 32 Cushman M, Yanez D, Psaty M, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP. for the Cardiovascular Health Study Investigators. Association of fibrinogen and coagulation factors VII and VIII with Cardiovascular Risk Factors in the Elderly: The Cardiovascular Health Study. Am J Epidemiol 1996; 143: 665-76.
• 33 Pankow JS, Folsom AR, Province MA, Rao DC, Eckfeldt J, Heiss G, Shahar E, Wu KK. Family history of coronary heart disease and hemostatic variables in middle-aged adults. Thromb Haemost 1997; 77: 87-93.
• 34 Hoffman CJ, Burns P, Lawson WE, Katz JP, Miller RH, Hultin MB. Plasma fibrinogen level is not elevated in young adults from families with premature ischemic heart disease. Arterioscler Thromb 1993; 13: 800-3.
• 35 Bara L, Nicaud V, Tiret L, Cambien F, Samama MM. on behalf of the EARS Group. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring - The EARS Study. Thromb Haemost 1994; 71: 434-40.
• 36 Folsom AR, Qamhieh HT, Flack JM, Hilner JE, Liu K, Howard BV, Tracy RP. Plasma fibrinogen: Levels and correlates in young adults. Am J Epidemiol 1993; 138: 1023-36.
• 37 Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338-42.
• 38 Sanchez-Bayle M, Cocho P, Baeza J, Vila S. and the Nino Jesus Group. Fibrinogen as a cardiovascular risk factor in Spanish children and adolescents. Am Heart J 1993; 126: 322-6.
• 39 Bonithon-Kopp C, Scarabin PY, Taquet A, Touboul PJ, Malmejac A, Guize L. Risk factors for early carotid atherosclerosis in middle-aged French women. Arterioscler Thromb 1991; 11: 966-702.
• 40 Prati P, Vanuzzo D, Casaroli M, Di Chiara A, De Biasi F, Feruglio GA, Touboul PJ. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke 1992; 23: 1705-11.